Dysregulation of iron metabolism in chronic kidney disease – hepcidin as a diagnostic biomarker in Iraqi adults – a case-control study
DOI:
https://doi.org/10.15584/ejcem.2026.1.4Abstract
Introduction and aim. Chronic kidney disease (CKD) is a global health burden, with iron deficiency (ID) being a prevalent but under-diagnosed comorbidity. Traditional biomarkers, such as serum ferritin and transferrin saturation, are confounded by inflammation, which limits diagnostic accuracy. Hepcidin, a key regulator of iron homeostasis, offers potential as a reliable biomarker; however, data from low- and middle-income countries (LMICs), including Iraq, remain scarce. This study assessed the diagnostic utility of hepcidin for CKD and its association with iron dysregulation in Iraqi adults, addressing regional gaps in biomarker validation and clinical application.
Material and methods. This case-control study (September 2024–February 2025) recruited 60 patients with CKD (stages 2–4) and 40 age-and sex-matched healthy controls. The exclusion criteria were recent transfusions, infections, or iron therapy. Serum hepcidin, ferritin, iron, Total Iron-Binding Capacity (TIBC), transferrin, and renal function indices were analyzed via enzyme-linked immunosorbent assay and standardized assays.
Results. CKD patients exhibited significantly elevated hepcidin (39.8±23.1 vs. 13.7±4.8 pg/mL, p<0.001) and ferritin (246±128 vs. 160±61 ng/mL, p<0.001) but lower serum iron (12.38±3.1 vs. 118±33.5 μg/dL, p<0.001), TIBC (347±109 vs. 385±62 μg/dL, p=0.004), and transferrin levels (224±74 vs. 258±39 mg/dL, p=0.005) than controls. Hepcidin levels increased progressively with CKD stage (p<0.001) and correlated strongly with eGFR (r=-0.800, p<0.001) and serum creatinine (r=0.702, p<0.001). At a cut-off of >25 pg/mL, hepcidin demonstrated 80% sensitivity and 100% specificity for CKD diagnosis, with an AUC of 0.86 (95% CI: 0.78–0.92, p<0.001).
Conclusion. Hepcidin demonstrated high diagnostic accuracy for CKD and was a superior indicator of iron metabolism dysregulation compared to traditional biomarkers. Its utility in resource-limited settings, such as Iraq, could enhance early CKD detection and guide management strategies, thereby addressing critical gaps in LMIC healthcare.
Downloads
References
Kalra PA. Iron deficiency in renal medicine. Iron Clin Pract. 2025:65-69. doi:10.1002/9781394210916.ch10
Vaidya SR, Aeddula NR. Chronic kidney disease. In: StatPearls [Internet]. StatPearls Publishing; 2024. Accessed July 1, 2025.
Aitken E, Anijeet H, Ashby D, et al. UK Kidney Association clinical practice guideline on vascular access for haemodialysis. BMC Nephrol. 2025;26(1):461. doi:10.1186/s12882-025-04374-y
Yan MT, Chao CT, Lin SH. Chronic kidney disease: strategies to retard progression. Int J Mol Sci. 2021;22(18):10084. doi:10.3390/ijms221810084
Guo M, He F, Zhang C. Molecular therapeutics for diabetic kidney disease: an update. Int J Mol Sci. 2024;25(18):10051. doi:10.3390/ijms251810051
Choukroun G, Kazes I, Dantal J, et al. Prévalence de la carence martiale dans une population de patients insuffisants rénaux chroniques non dialysés: étude nationale multicentrique observationnelle CARENFER. Néphrol Thérapeut. 2022;18(3):195-201. doi:10.1016/j.nephro.2021.12.003
Minutolo R, Grandaliano G, Di Rienzo P, et al. Prevalence, incidence, and treatment of anaemia in patients with non-dialysis-dependent chronic kidney disease: findings from a retrospective real-world study in Italy. J Nephrol. 2023;36(2):347-357. doi:10.1007/s40620-022-01475-x
George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Heal. 2017;2(2):e000256. doi:10.1136/bmjgh-2016-000256
Safiri S, Amiri F, Karamzad N, Sullman MJM, Kolahi AA, Abdollahi M. Burden and trends of dietary iron deficiency in the Middle East and North Africa region, 1990-2021. Front Nutr. 2025;11:1517478. doi:10.3389/fnut.2024.1517478
Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, von Stillfried S, Lammers T. Iron metabolism: pathophysiology and pharmacology. Trends Pharmacol Sci. 2021;42(8):640-656. doi:10.1016/j.tips.2021.05.001
Agarwal AK, Yee J. Hepcidin. Adv Chronic Kidney Dis. 2019;26(4):298-305. doi:10.1053/j.ackd.2019.04.005
Roy JE, Kalaiselvi VS, Shanthi B. Study on serum hepcidin level in chronic kidney disease. Ann Rom Soc Cell Biol. 2021;25(1):2715-2727.
Ustuner B, Bek S, Eren N, Bakirdogen S, Kalender B. Hepcidin and Vitamin D Levels: Mutual Effects in Anemia of Chronic Kidney Disease. Kocaeli Üniversitesi Sağlık Bilim Derg. 2021;7(2):110-114. doi:10.30934/kusbed.661316
Gao Z, Hu Y, Gao Y, Ma X, Hu Z. The association of hepcidin, reticulocyte hemoglobin equivalent and anemia-related indicators on anemia in chronic kidney disease. Medicine (Baltimore). 2023;102(17):e33558. doi:10.1097/MD.0000000000033558
Sobh MA, Imam HMK, Seddik MI, Sadek DEM. Role of Hepcidin as A Predictor for Iron Metabolism Disorders and Inflammation in Stage 4 Chronic Kidney Disease Patient with Anemia. Cuest Fisioter. 2025;54(4):4904-4912. doi:10.48047/CU
Głogowski T, Wojtaszek E, Malyszko J. Biomarkers of iron metabolism in chronic kidney disease. Int Urol Nephrol. 2021;53(5):935-944. doi:10.1007/s11255-020-02663-z
Mula-Abed WAS, Al Rasadi K, Al-Riyami D. Estimated glomerular filtration rate (eGFR): A serum creatinine-based test for the detection of chronic kidney disease and its impact on clinical practice. Oman Med J. 2012;27(2):108-113. doi:10.5001/omj.2012.23
Wong MMY, Tu C, Li Y, et al. Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J. 2020;13(4):613-624. doi:10.1093/ckj/sfz091
Kwiatkowska E, Opara M, Kwiatkowski S, Domański L, Marchelek-Myśliwiec M, Ciechanowski K. Is transferrin saturation a useful marker of iron metabolism in patients with chronic kidney disease treated with hemodialysis? Open Urol Nephrol J. 2019;12:1-7. doi:10.2174/1874303X01912010077
Zapora-Kurel A, Malyszko J. Novel iron biomarkers in chronic kidney disease. Wiad Lek. 2021;74(12):3230-3233. doi:10.36740/WLek202112119
Agarwal AK. Iron metabolism and management: focus on chronic kidney disease. Kidney Int Suppl. 2021;11(1):46-58. doi:10.1016/j.kisu.2020.12.003
Fujisawa H, Nakayama M, Haruyama N, et al. Association between iron status markers and kidney outcome in patients with chronic kidney disease. Sci Rep. 2023;13(1):18278. doi:10.1038/s41598-023-45580-8
Rashid RM, Al-Rubaie HA. Evaluation of transferrin saturation and serum ferritin in assessing body iron status in patients with end stage renal disease. Int J Clin Diagnostic Pathol. 2024;7(3):30-36. doi:10.33545/pathol.2024.v7.i3a.581
Al-Mashdali A, Alyafei T, Yassin M. The Superiority of T2* MRI Over Serum Ferritin in the Evaluation of Secondary Iron Overload in a Chronic Kidney Disease Patient: A Case Report. J Blood Med. 2021:665-670. doi:10.2147/JBM.S319591
Benjamin S, Assounga A. Transferrin levels are associated with malnutrition markers in hemodialysis patients in KwaZulu-Natal, South Africa. Ren Fail. 2024;46(1):2337292. doi:10.1080/0886022X.2024.2337292
Mercadal L, Metzger M, Haymann JP, et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One. 2014;9(6):e99781. doi:10.1371/journal.pone.0099781
Disease K. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.01
Suh SH, Oh TR, Choi HS, et al. Predictive Value of Serum Hepcidin Levels for the Risk of Incident End-Stage Kidney Disease in Patients with Chronic Kidney Disease: The KNOW-CKD. Kidney Dis. 2024;10(6):492-503. doi:10.1159/000542057
Niikura T, Maruyama Y, Nakashima S, et al. Hepcidin/ferritin ratios differ among non-dialyzed chronic kidney disease patients, and patients on hemodialysis and peritoneal dialysis. Ther Apher Dial. 2019;23(4):341-346. doi:10.1111/1744-9987.12773
Sonkar SK, Singh NK, Sonkar GK, et al. Association of hepcidin and anemia in early chronic kidney disease. Saudi J Kidney Dis Transpl. 2019;30(2):315-324. doi:10.4103/1319-2442.256838
Sonkar SK, Kumar A, Singh NK, Sonkar GK, Pandey S, Bhosale V. Role of Hepcidin on Response of Erythropoietin Stimulating Agents in Anaemic Advanced Chronic Kidney Disease Patients. J Clin Diagnostic Res. 2018;12(10):OC14-OC16. doi:10.7860/JCDR/2018/36051.12142
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
